Suns hire Cavs' Jordan Ott as new head coach
The post Suns hire Cavs' Jordan Ott as new head coach appeared first on ClutchPoints.
The Phoenix Suns have agreed to hire Cleveland Cavaliers assistant coach Jordan Ott as their new head coach, first reported by Shams Charania of ESPN.
Advertisement
Ott was a key part of Kenny Atkinson's staff this past season in Cleveland and contributed to the Cavs winning 64 games as one of the leading voices on their bench next to Atkinson, who was named the 2024-25 NBA Coach of the Year.
Johnnie Bryant, another Cavs assistant, was also a finalist for the Suns head coaching vacancy. Both Bryant and Ott met with owner Mat Ishbia, CEO Josh Bartelstein, and general manager Brian Gregory in Michigan on Tuesday for the final time before Phoenix decided who they wanted to hire.
Superstar guard Devin Booker was also involved in the search that led to an agreement with Otto to become the Suns' new head coach.
Before joining the Cavaliers for the 2024-25 season, Ott spent two years with the Los Angeles Lakers as an assistant on Darvin Ham's staff. He previously served as an assistant for the Brooklyn Nets from 2016 to 2022, as well as the video coordinator for the Atlanta Hawks from 2013 to 2016.
Advertisement
Ott, who originally graduated from Penn State, received his master's degree in athletic administration from Michigan State, continuing Ishbia's lineage of hiring fellow Spartan alumni. The Suns owner recently hired Gregory, who also attended Michigan State, as the team's newest general manager with James Jones moving into a senior advisor role with the franchise.
The new Suns head coach has been heavily regarded around the league for his devotion to player development and relationships with his team. As he takes over the role left behind by Mike Budenholzer, who was fired after the Suns missed the playoffs, Ott will be responsible for flipping the script in Phoenix and creating a new, positive atmosphere.
However, the immediate future of this organization is unknown due to the uncertainty surrounding Kevin Durant.
After appearing in serious trade conversations against his will before the trade deadline in February, the Suns are expected to part ways with Durant this offseason. Where Durant ends up remains a mystery, as the bigger question for Phoenix revolves around what value and assets they can get in return for the two-time Finals MVP in trade talks.
Advertisement
The Suns finished the 2024-25 season with a 36-46 record, their worst since the 2019-20 season.
Related: Kings rumors: Sacramento eyeing Suns guard in free agency
Related: NBA rumors: Spurs teased as Kevin Durant trade destination before draft
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Ex-Red Sox ace Chris Sale suffers fractured left ribcage on diving play
The Atlanta Braves have placed former Red Sox ace Chris Sale on the 15-day injured list with a fractured left ribcage. The 36-year-old lefty, who won the 2024 NL Cy Young, has a 2.52 ERA. 1.16 WHIP, .234 batting average against, 114 strikeouts and 26 walks in 15 starts. Advertisement Sale suffered the fracture when he dived for a ball hit to the right side of the mound by Mets star Juan Soto on Wednesday. Sale was able to complete the play for the first out of the ninth inning in a 5-0 win. He ended up recording the next out before being removed. He went 8 ⅔ scoreless innings and allowed five hits and one walk while striking out seven. This marks Sale's first IL stint in two seasons with the Braves. Boston traded him to Atlanta on Dec. 30, 2023 for infielder Vaughn Grissom. Sale spent most of his final four seasons with Boston on the IL because of multiple injuries, including Tommy John surgery in 2020. Advertisement The Braves did not give a timetable for his return. More Red Sox coverage Read the original article on MassLive.
Yahoo
29 minutes ago
- Yahoo
Universal Health Services, Inc.'s (NYSE:UHS) Intrinsic Value Is Potentially 34% Above Its Share Price
Universal Health Services' estimated fair value is US$229 based on 2 Stage Free Cash Flow to Equity Universal Health Services is estimated to be 25% undervalued based on current share price of US$172 Our fair value estimate is 1.8% higher than Universal Health Services' analyst price target of US$225 In this article we are going to estimate the intrinsic value of Universal Health Services, Inc. (NYSE:UHS) by taking the expected future cash flows and discounting them to their present value. We will use the Discounted Cash Flow (DCF) model on this occasion. There's really not all that much to it, even though it might appear quite complex. Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF ($, Millions) US$1.06b US$1.19b US$686.5m US$628.6m US$597.1m US$581.4m US$575.8m US$577.0m US$582.9m US$592.3m Growth Rate Estimate Source Analyst x1 Analyst x3 Analyst x2 Est @ -8.43% Est @ -5.02% Est @ -2.63% Est @ -0.96% Est @ 0.21% Est @ 1.03% Est @ 1.60% Present Value ($, Millions) Discounted @ 6.4% US$997 US$1.1k US$570 US$490 US$438 US$401 US$373 US$351 US$333 US$318 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$5.3b The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.4%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = US$592m× (1 + 2.9%) ÷ (6.4%– 2.9%) = US$18b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$18b÷ ( 1 + 6.4%)10= US$9.5b The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$15b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of US$172, the company appears a touch undervalued at a 25% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Universal Health Services as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.4%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. See our latest analysis for Universal Health Services Strength Earnings growth over the past year exceeded the industry. Debt is well covered by earnings and cashflows. Weakness Dividend is low compared to the top 25% of dividend payers in the Healthcare market. Opportunity Annual earnings are forecast to grow for the next 3 years. Good value based on P/E ratio and estimated fair value. Threat Annual earnings are forecast to grow slower than the American market. Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Can we work out why the company is trading at a discount to intrinsic value? For Universal Health Services, we've put together three essential factors you should explore: Risks: For example, we've discovered 1 warning sign for Universal Health Services that you should be aware of before investing here. Future Earnings: How does UHS's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NYSE every day. If you want to find the calculation for other stocks just search here. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
USA Today
31 minutes ago
- USA Today
NBA Finals referees: Who are the officials for Game 7 of Pacers-Thunder?
The NBA announced referees for Game 7 of the NBA Finals this morning, and to the pleasure of many fans, those names didn't include Scott Foster (sorry, Rick Carlisle). Instead, this winner-take-all game between the Oklahoma City Thunder and Indiana Pacers will be officiated by James Capers, Josh Tiven and Sean Wright, with James Williams serving as an alternate. Foster's omission does stand out a bit, as he was part of the crew with Tiven and Wright for Game 4, which also included Capers as the replay center referee. This time, Capers takes the floor and it'll be David Guthrie on replays. NBA Finals Game 7 referees
